Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22235474 | 0.88 | FLT3 (0.52) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL914773 | 0.86 | SRD5A2 (0.59) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL217459 | 0.85 | FLT3 (0.66) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL12388663 | 0.83 | CYP2D6 (0.59) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL6308070 | 0.82 | FLT3 (0.51) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL7044742 | 0.81 | SRD5A2 (0.53) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL28599963 | 0.81 | ULK1 (0.76) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL28581092 | 0.81 | ULK1 (1.00) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL28603485 | 0.81 | ULK1 (0.76) | ULK1KMT2AMEN1RCE1KDM4E | |
| SCHEMBL22620594 | 0.80 | ULK1 (0.49) | ULK1KMT2AMEN1RCE1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112358435-A | Substituted aromatic heterocyclic compound, preparation method, ULK1 inhibition and antitumor application | 中国医学科学院医药生物技术研究所 | 2021-02-12 | — | — | CN | claimed |
| CN-112358435-B | Substituted aromatic heterocyclic compound, preparation method, ULK1 inhibition and antitumor application | 中国医学科学院医药生物技术研究所 | 2023-01-10 | — | — | CN | disclosed |
| CN-112358435-A | Substituted aromatic heterocyclic compound, preparation method, ULK1 inhibition and antitumor application | 中国医学科学院医药生物技术研究所 | 2021-02-12 | — | — | CN | disclosed |
| EP-2471786-B1 | AMINOPYRAZOLE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-9102692-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-11 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-8829199-B2 | Aminopyrazole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2014-09-09 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208811-A1 | Aminopyrazole Derivative | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-16 | — | — | US | disclosed |
| EP-2471786-A1 | AMINOPYRAZOLE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | ULK1 4807/4885KMT2A 4109/4885MEN1 3891/4885 |
| US-20120208811-A1 | Aminopyrazole Derivative | FGFR1, FGFR3, FGFR4 | ULK1 1270/4885KMT2A 2297/4885MEN1 4119/4885 |
| US-20140315856-A1 | AMINOPYRAZOLE DERIVATIVE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL4I1, CYP3A43 | ULK1 1706/4885KMT2A 2547/4885MEN1 2623/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | ULK1 4816/4885KMT2A 4125/4885MEN1 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.